|
Delayed
Xetra
|
5-day change | 1st Jan Change | ||
| - EUR | -.--% |
|
-1.95% | -8.87% |
| 10/11/23 | Alvotech, Stada Get EU Panel Backing for Stelara Biosimilar | MT |
| 25/07/23 | Xbrane Biopharma and Stada consider options for ranibizumab | FW |
| Manager | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 61 | 31/08/2018 | |
Boris Döbler
DFI | Director of Finance/CFO | - | 31/12/2022 |
Miguel Fernandez
CTO | Chief Tech/Sci/R&D Officer | 61 | 31/12/2014 |
| Director | Title | Age | Since |
|---|---|---|---|
Jens Steegers
BRD | Director/Board Member | 46 | 03/06/2014 |
Eric Cornut
BRD | Director/Board Member | 69 | 25/08/2016 |
Günter von Au
CHM | Chairman | 75 | 26/09/2017 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -.--% | -1.95% | - | - | 5.73B | ||
| -1.61% | -0.15% | +11.45% | +60.09% | 46.78B | ||
| -1.02% | -1.90% | +35.99% | +99.64% | 37.88B | ||
| +2.19% | +3.65% | +10.70% | +80.29% | 11.82B | ||
| +1.32% | +2.09% | -11.64% | +12.41% | 11.61B | ||
| 0.00% | +0.57% | +18.78% | +148.82% | 9.12B | ||
| +0.39% | +2.08% | +29.58% | +38.20% | 7.38B | ||
| +1.30% | +1.17% | +16.08% | +187.41% | 7.12B | ||
| -0.06% | +2.97% | +38.90% | -18.37% | 7.21B | ||
| +1.38% | -2.74% | -42.62% | +6.68% | 4.99B | ||
| Average | +0.36% | +0.39% | +11.91% | +68.35% | 14.96B | |
| Weighted average by Cap. | -0.38% | -0.05% | +17.11% | +73.33% |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- SAZ Stock
Select your edition
All financial news and data tailored to specific country editions
















